Roivant Sciences Ltd. ROIV
Institutional shares held
456 Million
8.36M
calls
760K
puts
Total value of holdings
$7.75B
$142M
calls
$12.9M
puts
Market Cap
$12.1B
704,382,976
Shares Out.
Institutional ownership
64.75%
# of Institutions
362
We take great care to ensure that the data presented and summarized in this overview for Roivant Sciences Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ROIV
View all-
Sb Investment Advisers (Uk) LTD London, X060MShares$1.03 Billion5.36% of portfolio
-
Morgan Stanley New York, NY44.7MShares$765 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.3MShares$673 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$605 Million0.01% of portfolio
-
Viking Global Investors LP34.2MShares$586 Million1.22% of portfolio
-
Qvt Financial LP New York, NY29.4MShares$503 Million32.33% of portfolio
-
Rubric Capital Management LP New York, NY20.4MShares$349 Million5.29% of portfolio
-
State Street Corp Boston, MA19.8MShares$338 Million0.01% of portfolio
-
Patient Square Capital LP Menlo Park, CA12.5MShares$214 Million50.71% of portfolio
-
Two Seas Capital LP Rye, NY10.6MShares$181 Million2.22% of portfolio
Latest Institutional Activity in ROIV
Top Purchases
Top Sells
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Insider Transactions at ROIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 13
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
20,727
-1.36%
|
$331,632
$16.25 P/Share
|
|
Oct 13
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,727
+1.34%
|
$310,905
$15.85 P/Share
|
|
Oct 09
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
104,940
-6.52%
|
$1,679,040
$16.3 P/Share
|
|
Oct 09
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
104,940
+6.12%
|
$1,574,100
$15.85 P/Share
|
|
Oct 08
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
138,602
-8.43%
|
$2,217,632
$16.2 P/Share
|
|
Oct 08
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
138,602
+3.96%
|
$1,524,622
$11.65 P/Share
|
|
Oct 07
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
355,161
-19.09%
|
$5,682,576
$16.15 P/Share
|
|
Oct 07
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
355,161
+6.32%
|
$3,196,449
$9.05 P/Share
|
|
Oct 06
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
171,396
-10.22%
|
$2,742,336
$16.34 P/Share
|
|
Oct 06
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
171,396
+3.28%
|
$1,542,564
$9.05 P/Share
|
|
Sep 28
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,341
-0.6%
|
$35,115
$15.17 P/Share
|
|
Sep 23
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
611,000
-28.88%
|
$8,554,000
$14.83 P/Share
|
|
Sep 22
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
416,182
-8.5%
|
$6,242,730
$15.0 P/Share
|
|
Sep 22
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
562,374
+9.89%
|
$1,687,122
$3.85 P/Share
|
|
Sep 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.54%
|
$31,935
$15.04 P/Share
|
|
Sep 19
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
683,818
-25.77%
|
$9,573,452
$14.95 P/Share
|
|
Sep 19
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000,000
+27.37%
|
$3,000,000
$3.85 P/Share
|
|
Sep 18
2025
|
Matthew Gline CEO |
BUY
Open market or private purchase
|
Direct |
3,315
+0.02%
|
$49,725
$15.07 P/Share
|
|
Sep 10
2025
|
Epperly Melissa B, |
SELL
Other acquisition or disposition
|
Direct |
1,661
-2.89%
|
$21,593
$13.77 P/Share
|
|
Sep 10
2025
|
Epperly Melissa B, |
BUY
Grant, award, or other acquisition
|
Direct |
14,524
+20.16%
|
-
|
Last 12 Months Summary
Buy / Acquisition
36M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 14.3M shares |
|---|---|
| Open market or private purchase | 3.32K shares |
| Exercise of conversion of derivative security | 8.33M shares |
| Bona fide gift | 13.4M shares |
Sell / Disposition
120M
Shares
From
20
Insiders
| Payment of exercise price or tax liability | 253K shares |
|---|---|
| Other acquisition or disposition | 94.6M shares |
| Open market or private sale | 12.1M shares |
| Bona fide gift | 13.4M shares |